

# Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



# Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

# Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

## SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



# PRODUCT INFORMATION



## PCI 27483

Item No. 21334

CAS Registry No.: 871266-63-6

Formal Name: N-[2-[5-[6-(aminoiminomethyl)-1H-

> benzimidazol-2-yl]-5'-(aminosulfonyl)-2',6-dihydroxy[1,1'-biphenyl]-3-yl]

acetyl]-L-aspartic acid

 $C_{26}H_{24}N_6O_9S$ MF:

FW: 596.6 **Purity:** ≥95%

λ<sub>max</sub>: 230, 307, 340 nm UV/Vis.: Supplied as: A crystalline solid

-20°C Storage:

Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when

stored properly

#### **Laboratory Procedures**

PCI 27483 is supplied as a crystalline solid. A stock solution may be made by dissolving the PCI 27483 in the solvent of choice. PCI 27483 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of PCI 27483 in these solvents is approximately 10 and 1 mg/ml, respectively.

PCI 27483 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, PCI 27483 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. PCI 27483 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

#### Description

PCI 27483 is a small molecule inhibitor of activated coagulation factor VIIa with antithrombotic effects in a baboon model of arterial thrombosis. 1 It also inhibits the growth of BxPC3 xenografts by 42 and 85% at doses of 60 and 90 mg/kg, respectively.<sup>2</sup>

#### References

- 1. Gómez-Outes, A., Suárez-Gea, L., Lecumberri, R., et al. New parenteral anticoagulants in development. Ther. Adv. Cardiovasc. Disc. 5(1), 33-59 (2011).
- 2. Prescott, J., Thiemann, P., and Loury, D. PCI-27483, a small molecule inhibitor of Factor VIIa, inhibits growth of BxPC3 pancreatic adenocarcinoma xenograft tumors. AACR Annual Meeting (2008).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 03/01/2017

#### **CAYMAN CHEMICAL**

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM